See more : Zen Voce Corporation (3581.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Willow Biosciences Inc. (CANSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Willow Biosciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Maxar Technologies Inc. (MAXR.TO) Income Statement Analysis – Financial Results
- SGT German Private Equity GmbH & Co. KGaA (GAI.DE) Income Statement Analysis – Financial Results
- Rex Minerals Limited (RXRLF) Income Statement Analysis – Financial Results
- BML, Inc. (4694.T) Income Statement Analysis – Financial Results
- Eternit S.A. (ETER3.SA) Income Statement Analysis – Financial Results
Willow Biosciences Inc. (CANSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.willowbio.com
About Willow Biosciences Inc.
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17M | 821.00K | 133.00K | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.83M | 7.47M | 11.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -659.00K | -6.65M | -11.40M | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | -116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -56.23% | -810.23% | -8,571.43% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.80M | 7.47M | 11.51M | 7.26M | 2.67M | 387.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.60M | 8.29M | 7.79M | 6.42M | 8.24M | 961.60K | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 887.93K | 2.00M | 1.01M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 420.00K | 808.00K | 817.00K | 0.00 | 0.00 | 588.31K | 0.00 | 31.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 89.13K | 76.39K | 36.47K | 87.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 7.10K |
| SG&A | 6.02M | 9.10M | 8.60M | 6.42M | 8.24M | 1.55M | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 977.07K | 2.08M | 1.04M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 2.29K | 7.10K |
| Other Expenses | 1.54M | 0.00 | -22.00K | 0.00 | 0.00 | 0.00 | 6.61K | 30.89K | 20.08K | 60.32K | 75.13K | 50.00K | 0.00 | 3.51K | 93.90K | -84.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Cost & Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Interest Income | 267.00K | 300.00K | 414.00K | 155.00K | 112.90K | 0.00 | 0.00 | 0.00 | 2.00 | 115.00 | 238.00 | 43.00 | 1.89K | 7.35K | 1.77K | 17.60K | 14.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.56K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 142.00K | 26.00K | 27.00K | 40.00K | 48.14K | 0.00 | 21.96K | 2.26K | 0.00 | 0.00 | 1.78K | 11.41K | 28.14K | 1.28K | 1.68K | 1.48K | 1.30K | 234.00 | 248.00 | 24.13K | 126.51K | 0.00 | 0.00 | 3.19K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.83M | 2.65M | 3.19M | 3.18M | 2.17M | 46.39K | 38.38K | 30.18K | 609.49K | 116.00 | 382.00 | 787.00 | 1.17K | 2.48K | 3.73K | 3.87K | 1.03K | 0.00 | 0.00 | 0.00 | 192.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.63M | -15.45M | -2.92M | -30.72M | -43.93M | -1.60M | -1.52M | -1.07M | -4.37M | -865.26K | -962.89K | -625.25K | -951.54K | -969.72K | -1.98M | -1.11M | -2.07M | -420.83K | -442.64K | -193.66K | 13.12K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| EBITDA Ratio | -992.06% | -1,882.34% | -14,712.78% | -135,090.00% | -235,507.88% | -9,449.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.18M | -18.39M | -23.33M | -23.06M | -46.15M | -1.64M | -622.25K | -873.74K | -721.12K | -925.80K | -1.04M | -626.08K | -954.60K | -980.82K | -2.08M | -1.05M | -2.07M | -420.83K | -442.64K | -193.66K | -179.62K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| Operating Income Ratio | -1,124.74% | -2,240.32% | -17,541.35% | -230,610.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 148.00K | 3.63M | 17.19M | -10.89M | 561.00K | 0.00 | -931.67K | -1.46M | -85.05K | 60.43K | -348.54K | -1.17M | -462.51K | -2.35M | -1.13M | -313.85K | 25.48K | -234.00 | -248.00 | 0.00 | -96.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -13.03M | -14.76M | -6.14M | -33.95M | -46.15M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.33M | -3.21M | -1.36M | -2.05M | -421.06K | -442.89K | 0.00 | -275.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,112.12% | -1,797.93% | -4,616.54% | -339,460.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.00K | 53.00K | 27.00K | 40.00K | -1.58M | -114.75K | -9.81K | 2.26K | -2.00 | 60.32K | 76.90K | 11.41K | 28.14K | -118.00K | -157.00K | -211.04K | -394.90K | -16.65K | -52.54K | 217.79K | 30.14K | 70.21K | 163.31K | 183.16K | 114.44K | 202.12K |
| Net Income | -13.03M | -14.81M | -6.14M | -33.95M | -44.57M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.22M | -3.06M | -1.15M | -1.65M | -404.41K | -390.35K | -217.79K | -306.13K | -70.21K | -163.31K | -183.16K | -114.44K | -202.12K |
| Net Income Ratio | -1,111.69% | -1,804.38% | -4,616.54% | -339,460.00% | -972,220.55% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -97.47 | -17.50 |
| EPS Diluted | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -96.98 | -17.50 |
| Weighted Avg Shares Out | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.17K | 11.55K |
| Weighted Avg Shares Out (Dil) | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.18K | 11.55K |
Willow Biosciences secures contracts valued at $1M during 2Q
Willow Biosciences told investors that during the second quarter, it closed three new contracts that are expected to bring in more than $1 million in near-term research and development (R&D)/milestone revenue and, if successful, will generate long-term commercial revenue. Additionally,...
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
New partnerships and contracts expected to bring in over $1 million in near-term R&D/milestone revenue and generate long term commercial revenue SUNNYVALE, Calif. , Aug. 8, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused...
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9
President and CEO Dr. Chris Savile to provide business update at event open to all investors SUNNYVALE, Calif. , Aug. 2, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing...
Willow Biosciences and Kalsec move forward with program for large volume savory foods opportunity
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it is advancing its functional ingredient development program for a large-volume savory foods opportunity with Kalsec Inc, a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients...
WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS
Program further validates Willow's technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation KALAMAZOO, Mich. and SUNNYVALE, Calif.
Willow Biosciences signs MSA with innovative biotech company to develop ingredients for age-related disease
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has executed a Master Services Agreement (MSA) with an innovative biotech company to develop ingredients for age-related disease. The company said it aims to develop precision fermentation processes for a class of...
Willow Biosciences and Kalsec collaborate on new enzyme for advanced beverage ingredient
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has entered into a follow-on Master Services Agreement with Kalsec to develop an enzyme used in the biocatalytic production of a new, advanced ingredient used in natural beverage applications. This is the second...
Willow Biosciences forecasts ‘significant' revenue growth in 2023
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has said it expects to achieve “significant” growth in revenue as well as a “demonstrable” reduction in cash burn for 2023, as steps taken to optimize its business have begun to pay off. The upbeat...
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS
Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue growth for 2023 Previous steps taken to further optimize Willow’s business, focus on near-term revenue generation and reduce cash burn are paying off MOUNTAIN VIEW, Calif.,...
Source: https://incomestatements.info
Category: Stock Reports